PET-CT Imaging in Hypertrophic Cardiomyopathy: A Narrative Review on Risk Stratification and Prognosis

Overview

Journal Diagnostics (Basel)

Date 2025 Jan 25

PMID 39857018

Authors

Patricia Marques-Alves

Lino Goncalves

Maria Joao Ferreira

Affiliations

Soon will be listed here.

Abstract

Hypertrophic cardiomyopathy (HCM) is a heterogeneous cardiac disease and one of its major challenges is the limited accuracy in stratifying the risk of sudden cardiac death (SCD). Positron emission tomography (PET), through the evaluation of myocardial blood flow (MBF) and metabolism using fluorodeoxyglucose (FDG) uptake, can reveal microvascular dysfunction, ischemia, and increased metabolic demands in the hypertrophied myocardium. These abnormalities are linked to several factors influencing disease progression, including arrhythmia development, ventricular dilation, and myocardial fibrosis. Fibroblast activation can also be evaluated using PET imaging, providing further insights into early-stage myocardial fibrosis. Conflicting findings underscore the need for further research into PET's role in risk stratification for HCM. If PET can establish a connection between parameters such as abnormal MBF or increased FDG uptake and SCD risk, it could enhance predictive accuracy. Additionally, PET holds significant potential for monitoring therapeutic outcomes. The aim of this review is to provide a comprehensive overview of the most significant data on disease progression, risk stratification, and prognosis in patients with HCM using cardiac PET-CT imaging.

References

Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici P . Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003; 349(11):1027-35. DOI: 10.1056/NEJMoa025050. View

Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G . The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012; 53(2):241-8. DOI: 10.2967/jnumed.111.090662. View

Shi X, Lin X, Huo L, Li X . Cardiac fibroblast activation in dilated cardiomyopathy detected by positron emission tomography. J Nucl Cardiol. 2020; 29(2):881-884. DOI: 10.1007/s12350-020-02315-w. View

Funabashi N, Nakagawa K, Komuro I . Partial myocardial fibrosis in hypertrophic cardiomyopathy demonstrated by 18F-fluoro-deoxyglucose positron emission tomography and multislice computed tomography. Int J Cardiol. 2005; 107(2):284-6. DOI: 10.1016/j.ijcard.2005.01.069. View

Norikane T, Yamamoto Y, Takami Y, Mitamura K, Tani R, Nishiyama Y . Occasionally increased F-FDG uptake in apical hypertrophic cardiomyopathy on serial follow-up PET/CT. J Nucl Cardiol. 2019; 26(6):2125-2128. DOI: 10.1007/s12350-019-01623-0. View

Maron B, Rowin E, Casey S, Link M, Lesser J, Chan R . Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. J Am Coll Cardiol. 2015; 65(18):1915-28. DOI: 10.1016/j.jacc.2015.02.061. View

Elliott P, Anastasakis A, Borger M, Borggrefe M, Cecchi F, Charron P . 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35(39):2733-79. DOI: 10.1093/eurheartj/ehu284. View

Xie B, Wang J, Xi X, Guo X, Chen B, Li L . Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging. Eur J Nucl Med Mol Imaging. 2022; 49(8):2786-2797. DOI: 10.1007/s00259-021-05674-9. View

Maron B, McKenna W, Danielson G, Kappenberger L, Kuhn H, Seidman C . American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the.... J Am Coll Cardiol. 2003; 42(9):1687-713. DOI: 10.1016/s0735-1097(03)00941-0. View

10.

Lu D, Yalcin H, Sivalokanathan S, Greenland G, Vasquez N, Yalcin F . Higher incidence of vasodilator-induced left ventricular cavity dilation by PET when compared to treadmill exercise-ECHO in hypertrophic cardiomyopathy. J Nucl Cardiol. 2018; 27(6):2031-2043. DOI: 10.1007/s12350-018-01521-x. View

11.

Panovsky R, Pleva M, Feitova V, Kruzliak P, Meluzin J, Kincl V . The prognostic impact of myocardial late gadolinium enhancement. Cardiol Rev. 2014; 22(3):128-39. DOI: 10.1097/CRD.0000000000000002. View

12.

Krams R, Kofflard M, Duncker D, von Birgelen C, Carlier S, Kliffen M . Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation. 1998; 97(3):230-3. DOI: 10.1161/01.cir.97.3.230. View

13.

Elliott P, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna W . Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999; 33(6):1596-601. DOI: 10.1016/s0735-1097(99)00056-x. View

14.

Katagiri M, Nakahara T, Murata M, Ogata Y, Matsusaka Y, Iwabuchi Y . Incidental spade-shaped FDG uptake in the left ventricular apex suggests apical hypertrophic cardiomyopathy. Ann Nucl Med. 2017; 31(5):399-406. DOI: 10.1007/s12149-017-1167-2. View

15.

Kagaya Y, Ishide N, Takeyama D, Kanno Y, Yamane Y, Shirato K . Differences in myocardial fluoro-18 2-deoxyglucose uptake in young versus older patients with hypertrophic cardiomyopathy. Am J Cardiol. 1992; 69(3):242-6. DOI: 10.1016/0002-9149(92)91313-s. View

16.

Maron B, Olivotto I, Spirito P, Casey S, BELLONE P, Gohman T . Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000; 102(8):858-64. DOI: 10.1161/01.cir.102.8.858. View

17.

Mentias A, Raeisi-Giglou P, Smedira N, Feng K, Sato K, Wazni O . Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function. J Am Coll Cardiol. 2018; 72(8):857-870. DOI: 10.1016/j.jacc.2018.05.060. View

18.

Olivotto I, Maron M, Adabag A, Casey S, Vargiu D, Link M . Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005; 46(3):480-7. DOI: 10.1016/j.jacc.2005.04.043. View

19.

Takeishi Y, Masuda A, Kubo H, Tominaga H, Oriuchi N, Takenoshita S . Cardiac imaging with F-fluorodeoxyglucose PET/MRI in hypertrophic cardiomyopathy. J Nucl Cardiol. 2016; 24(5):1827-1828. PMC: 5629240. DOI: 10.1007/s12350-016-0686-x. View

20.

Xu Y, Guo Y, Yang M . Heterogeneous Uptake of Al 18 F-NOTA-FAPI and 18 F-FDG in Apical Aneurysm in Apical Hypertrophic Cardiomyopathy. Clin Nucl Med. 2024; 49(12):e715-e717. DOI: 10.1097/RLU.0000000000005530. View